PUBBLICAZIONI GISCAD

pagina 2

Digestive and Liver Disease 2016 - http://dx.doi.org/10.10167j.dld.2016.11.010

· 

Borderline resectable pancreatic cancer: More than an anatomical concept

Fausto Petrelli, Alessandro Inno, Sandro Barni, Antonio Ghidini, Roberto Labianca, Massimo Falconi, Michele Reni, Stefano Cascinu on behalf of GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) and San Raffaele Hospital

· 

Phase III trial comparing 3 to 6 months pf adjuvant FOLFOX4/XELOX in stage II - III colon cancer, safety and compliance in the TOSCA trial

Lonardi S, Sombrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R; TOSCA (Three Or Six Colon Adjuvant) Investigators, Italy.

Ann Onco. Volume 27 | No. 11 |Novembre 2016

· 

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trial From the Adjuvant Colon Cancer Endpoints Database

Winson Y. Chung, Lindsay A. Renfro, David Kerr, Aimery de Gramont, Leonard B. Saltz, Axel Grothey, Steven R. Alberts, Thierry Andre, Katherine A Guthrie, Roberto Labianca, Guido Francini, Jean-Francois Seitz, Chris O'Callaghan, Chris Twelves, Eric Van Cutsem, Daniel G. Haller, Greg Yothers and Daniel J. Sargent

European Journal of Cancer 81 (2017) 174e182

· 

The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib

Luca Faloppi, Maristella Bianconi, Riccardo Giampieri, Alberto Sobrero, Roberto Labianca, Daris Ferrari, Sandro Barni, Enrico Aitini, Alberto Zaniboni, Corrado Boni, Francesco Caprioni, Stefani Mosconi, Silvia Fanello, Rossana Berardi, Alessandro Bittoni, Kalliopi Andrikou, Michela Cinquini, Valter Torri, Mario Scartozzi, Stefano Cascinu on behalf of the Italia Group  for the Study of Digestive Tract Cancer (GISCAD)

Oncotarget, Advance Pubblications 2015

Pancreas 2015; 44: 515-521

· 

FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer

A Meta - Analytical Review of Published Studies

Fausto Petrelli, MD, Andrea Coinu, Karen Borgonovo, MD, Mary Cabiddu, MD, Mara Ghilardi, MD, Veronica Lonati, Biologist, Enrico Aitini, MD and Sandro Barni, MD, on behalf of Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD)